Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. - Wikidata - wikimedia - TriplyDB

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

http://www.wikidata.org/entity/Q37524313

about

Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo The role of Fc-FcγR interactions in IgG-mediated microbial neutralization Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice.Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.EndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycans Microscale purification of antigen-specific antibodies.Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.Biophysical and Functional Characterization of Rhesus Macaque IgG Subclasses.LILR-B1 blocks activating FcγR signaling to allow antibody dependent enhancement of dengue virus infection.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.Type I and type II Fc receptors regulate innate and adaptive immunity.A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome.Mouse and human FcR effector functions.Fcγ receptor pathways during active and passive immunization.Signaling by Antibodies: Recent Progress.Beyond Viral Neutralization.Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.Beyond binding: antibody effector functions in infectious diseases.Fcγ Receptor Function and the Design of Vaccination Strategies.Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection

P2860

Q24568302-9B2AB550-D5CB-433B-B5D6-09471B68CC81 Q26797466-0E947D68-F1A7-4AB5-A094-4590BEFD1C10 Q26863621-4DC39E40-A774-4F30-9211-6185198F4C5E Q33751822-1B75CBCD-9BE8-4009-9A49-309779E10185 Q33845127-5E25A2B8-F3EA-4888-A3FB-9794D34AA7E6 Q34204325-F4DCDB8E-6BF9-4BEF-B84A-BCBBD3C29A22 Q35569901-67596306-5DDD-495A-97A3-AD047651007B Q35686671-F729402E-1572-45AB-BC1F-21F0822CDFB8 Q36157114-879A22C7-1453-4EEC-AF73-1699303ABEFD Q36624176-1D104A10-64A8-4A52-B1D7-BA2F7250F900 Q37497214-6B35186E-6D3A-45B8-B0CD-A4EC3BE2FD02 Q37599853-C2F8719C-305A-4178-AD48-8206DF6F86AE Q37621530-DBE42F84-7C23-4F02-919E-5773BB594567 Q37677278-BBBB8508-F3E5-41FC-9E7B-C5ECB0ABCDA6 Q38232105-2D9FD986-4A22-4D4B-9505-BC850FC85EDF Q38542411-E8F5DD9B-981B-4B10-B300-E6B09B0B5236 Q38615349-9EFA9F9E-3A44-4958-BACA-8717D49FD21E Q38615357-314B5E60-BEC8-4B52-A8FC-6FEA9A66FBE0 Q39264890-9FAFA669-6571-4D9B-AC2C-51636498B7C9 Q40373085-F3EC06BA-4A1B-497E-8935-60C08DA72BD8 Q47190029-C42C8919-BC04-431D-9F42-43A5A1AC0FB1 Q47602559-37939397-689B-438E-9F26-E3DD2503664B Q47945550-50C1E319-F5CD-49D5-8595-CA9D2BE3498E Q57059896-572700A7-0E28-4F50-A965-885C5452050D

P2860

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

http://www.wikidata.org/entity/Q37524313

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

@en

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

@nl

type

label

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

@en

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

@nl

prefLabel

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

@en

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

@nl

P1433

Q37524313-833B6702-B10E-49A1-A2CD-F949E0962D96

P1476

Q37524313-463CF6EE-7154-4493-AB68-9FBC5F5992B8

P2093

Q37524313-0C28FF01-B2E4-481A-B63E-319658C5E292

Q37524313-63E1C738-3755-495D-AD43-041B754C5331

Q37524313-B11BAAA8-99CF-489B-A012-5F96037CE792

Q37524313-EA0DB234-C6AD-4A84-9AF2-9F5737F4BEC5

P2860

Q37524313-00C74256-F693-4A80-A2B1-3420394F181F

Q37524313-1A7BD22D-EAC6-4E77-8344-42B9748A68B2

Q37524313-1F78503A-5878-44E8-B95F-AF4106CC4104

Q37524313-2231A1D5-D98E-4D1A-B9F4-0DAB487A7378

Q37524313-227415B4-AC03-48F0-8DB8-BD8FA9EE3BDF

Q37524313-238F7F22-87E7-4749-93AE-39CE3F2F2E32

Q37524313-25DFD58F-8974-429A-8F76-72332CB381BC

Q37524313-2FE35373-D23F-430E-A24B-E31F5A807234

Q37524313-4094E01E-6FFF-4BD9-BA2B-6BB33629D0FF

Q37524313-4F98EFEC-E587-4A30-8756-F5ED062101D6

P304

Q37524313-D0AAE85B-3745-424D-97FD-C77B2B3687DA

P31

Q37524313-E7855BB7-1AF2-4AC5-84E1-DC1B959599FC

P356

Q37524313-C9056998-0262-4210-A9F7-EFD0DB962A96

P407

Q37524313-4DEDFB80-07B8-4521-B91A-BFF9503DA976

P433

Q37524313-5F516588-162B-449A-801D-F9586C9B8838

P478

Q37524313-0A31689C-DFDE-4690-B4B5-A6884DA0F84B

P50

Q37524313-F29D2C7C-AC91-4D9D-AA4E-8C2EC43C5DBE

P577

Q37524313-16F54547-4F84-494D-AFD8-51DC523FD47B

P698

Q37524313-CF189A79-B56A-4709-8D66-01103EAF2C5F

P921

Q37524313-0908F3D6-9776-47F8-B878-11F3D3C47348

P932

Q37524313-0272F56B-C702-49E6-B447-1306DCA1E6CF

P356

P1433

Journal of Clinical Investigation

P1476

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

@en

P2093

Jeffrey V Ravetch

http://www.w3.org/2001/XMLSchema#string

Nareen Abboud

http://www.w3.org/2001/XMLSchema#string

Siu-Kei Chow

http://www.w3.org/2001/XMLSchema#string

Stylianos Bournazos

http://www.w3.org/2001/XMLSchema#string

P2860

Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus

Complement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile Virus

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge

Production and characterisation of a neutralising chimeric antibody against botulinum neurotoxin A

Fcgamma receptors as regulators of immune responses

Comparison of three anthrax toxin neutralization assays

Evaluation of Fab and F(ab')2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2.

A requirement for FcγR in antibody-mediated bacterial toxin neutralization.

Engineered antibody Fc variants with enhanced effector function.

P304

725-729

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI72676

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Arturo Casadevall

P577

2014-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24401277

http://www.w3.org/2001/XMLSchema#string

P921

P932

3904629

http://www.w3.org/2001/XMLSchema#string